Lessee, Operating Lease, Liability, Undiscounted Excess Amount of Inhibikase Therapeutics, Inc. from 30 Sep 2022 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
Summary
Inhibikase Therapeutics, Inc. quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount in USD history and change rate from 30 Sep 2022 to 30 Jun 2025.
  • Inhibikase Therapeutics, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount for the quarter ending 30 Jun 2025 was $378, a 97% decline year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Quarterly (USD)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, YoY Quarterly Change (%)

Inhibikase Therapeutics, Inc. Quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $378 -$12,338 -97% 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $1,872 -$16,442 -90% 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $4,449 -$20,393 -82% 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $8,078 -$24,197 -75% 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $12,716 -$27,858 -69% 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 $18,314 -$31,379 -63% 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $24,842 -$34,767 -58% 31 Dec 2023 10-K 27 Mar 2024 2023 FY
Q3 2023 $32,275 -$38,023 -54% 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $40,574 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $49,693 31 Mar 2023 10-Q 15 May 2023 2023 Q1
Q4 2022 $59,609 31 Dec 2022 10-K 31 Mar 2023 2022 FY
Q3 2022 $70,298 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.